News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
658,134 Results
Type
Article (56794)
Company Profile (227)
Press Release (601100)
Multimedia
Podcasts (158)
Webinars (25)
Section
Business (175342)
Career Advice (2510)
Deals (32245)
Drug Delivery (143)
Drug Development (81748)
Employer Resources (160)
FDA (17091)
Job Trends (13821)
News (315891)
Policy (34266)
Tag
Academia (2693)
Academic (1)
Accelerated approval (26)
Adcomms (35)
Allergies (128)
Alliances (46092)
ALS (167)
Alzheimer's disease (1760)
Antibody-drug conjugate (ADC) (304)
Approvals (17187)
Artificial intelligence (502)
Autoimmune disease (131)
Automation (29)
Bankruptcy (328)
Best Places to Work (10429)
BIOSECURE Act (23)
Biosimilars (186)
Biotechnology (154)
Bladder cancer (144)
Brain cancer (61)
Breast cancer (590)
Cancer (4498)
Cardiovascular disease (390)
Career advice (2126)
Career pathing (40)
CAR-T (262)
CDC (59)
Celiac Disease (1)
Cell therapy (710)
Cervical cancer (33)
Clinical research (69029)
Collaboration (1518)
Company closure (4)
Compensation (1038)
Complete response letters (65)
COVID-19 (2832)
CRISPR (91)
C-suite (703)
Cystic fibrosis (143)
Data (5674)
Decentralized trials (2)
Denatured (49)
Depression (130)
Diabetes (473)
Diagnostics (6020)
Digital health (36)
Diversity (11)
Diversity, equity & inclusion (43)
Drug discovery (252)
Drug pricing (206)
Drug shortages (36)
Duchenne muscular dystrophy (222)
Earnings (70552)
Editorial (60)
Employer branding (20)
Employer resources (144)
Events (99275)
Executive appointments (936)
FDA (19891)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (21)
Funding (1323)
Gene editing (195)
Generative AI (46)
Gene therapy (592)
GLP-1 (1063)
Government (4548)
Grass and pollen (8)
Guidances (372)
Healthcare (17008)
HIV (52)
Huntington's disease (45)
IgA nephropathy (80)
Immunology and inflammation (273)
Immuno-oncology (39)
Indications (76)
Infectious disease (3082)
Inflammatory bowel disease (185)
Inflation Reduction Act (16)
Influenza (99)
Intellectual property (212)
Interviews (459)
IPO (15579)
IRA (59)
Job creations (3748)
Job search strategy (1753)
Kidney cancer (16)
Labor market (75)
Layoffs (631)
Leadership (38)
Legal (8179)
Liver cancer (91)
Longevity (12)
Lung cancer (627)
Lymphoma (352)
Machine learning (38)
Management (55)
Manufacturing (701)
MASH (163)
Medical device (12354)
Medtech (12386)
Mergers & acquisitions (17634)
Metabolic disorders (1250)
Multiple sclerosis (150)
NASH (23)
Neurodegenerative disease (316)
Neuropsychiatric disorders (84)
Neuroscience (2933)
NextGen: Class of 2025 (5787)
Non-profit (4320)
Now hiring (38)
Obesity (609)
Opinion (320)
Ovarian cancer (140)
Pain (184)
Pancreatic cancer (194)
Parkinson's disease (268)
Partnered (27)
Patents (454)
Patient recruitment (384)
Peanut (55)
People (53177)
Pharmaceutical (47)
Pharmacy benefit managers (30)
Phase I (21229)
Phase II (30019)
Phase III (23133)
Pipeline (3793)
Policy (318)
Postmarket research (2920)
Preclinical (9108)
Press Release (61)
Prostate cancer (224)
Psychedelics (51)
Radiopharmaceuticals (275)
Rare diseases (791)
Real estate (5295)
Recruiting (65)
Regulatory (25629)
Reports (40)
Research institute (2471)
Resumes & cover letters (410)
Rett syndrome (23)
RNA editing (14)
RSV (75)
Schizophrenia (147)
Series A (223)
Series B (166)
Service/supplier (12)
Sickle cell disease (97)
Special edition (24)
Spinal muscular atrophy (171)
Sponsored (46)
Startups (3432)
State (1)
Stomach cancer (19)
Supply chain (100)
Tariffs (97)
The Weekly (107)
Vaccines (1072)
Venture capital (79)
Weight loss (427)
Women's health (66)
Worklife (21)
Date
Today (117)
Last 7 days (590)
Last 30 days (2428)
Last 365 days (30745)
2025 (30024)
2024 (34720)
2023 (38973)
2022 (49767)
2021 (53530)
2020 (51064)
2019 (42162)
2018 (32109)
2017 (31979)
2016 (30679)
2015 (34508)
2014 (27586)
2013 (23027)
2012 (24681)
2011 (25421)
2010 (23665)
Location
Africa (858)
Alabama (78)
Alaska (6)
Arizona (234)
Arkansas (12)
Asia (40522)
Australia (6915)
California (10142)
Canada (2766)
China (1007)
Colorado (394)
Connecticut (467)
Delaware (313)
Europe (93363)
Florida (1521)
Georgia (313)
Hawaii (3)
Idaho (48)
Illinois (741)
India (56)
Indiana (462)
Iowa (21)
Japan (365)
Kansas (115)
Kentucky (37)
Louisiana (22)
Maine (75)
Maryland (1306)
Massachusetts (7451)
Michigan (269)
Minnesota (557)
Mississippi (5)
Missouri (130)
Montana (26)
Nebraska (25)
Nevada (106)
New Hampshire (69)
New Jersey (2807)
New Mexico (28)
New York (2692)
North Carolina (1386)
North Dakota (8)
Northern California (4887)
Ohio (291)
Oklahoma (17)
Oregon (37)
Pennsylvania (2010)
Puerto Rico (20)
Rhode Island (40)
South America (1195)
South Carolina (58)
South Dakota (1)
Southern California (3929)
Tennessee (144)
Texas (1552)
United States (36282)
Utah (265)
Virginia (241)
Washington D.C. (74)
Washington State (824)
West Virginia (4)
Wisconsin (97)
Wyoming (1)
658,134 Results for "alzheimer s drug discovery foundation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the 2025 Clinical Trials on Alzheimer’s Disease conference continues following two disappointing readouts; and Novo Nordisk’s amycretin yields promising weight loss results.
December 3, 2025
·
1 min read
·
Heather McKenzie
Alzheimer’s disease
I Remember Aduhelm. The Return of Roche in Alzheimer’s Is a Turning Point
After covering the Alzheimer’s space through every high and low,
BioSpace
’s Annalee Armstrong welcomes back Roche for the 2026 Alzheimer’s Renaissance.
December 2, 2025
·
2 min read
·
Annalee Armstrong
Earnings
As Biogen Nears Presymptomatic Alzheimer’s Readout for Leqembi, Can Doctors Be Convinced?
To expand the population for the anti-amyloid Alzheimer’s drugs, Lilly and Biogen are testing presymptomatic patients. Will doctors be open to this paradigm-shifting change?
October 30, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Indivi Secures CHF15 Million Investment to Accelerate the Discovery of Treatment Response Biomarkers in Neuroscience Drug Development, Targeting Alzheimer’s Disease
November 12, 2025
·
2 min read
Alzheimer’s disease
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of the monoclonal antibody drug class that has led to several deaths.
July 9, 2025
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
November 24, 2025
·
3 min read
·
Heather McKenzie
Press Releases
Foundation Medicine and Manifold Partner to Accelerate Drug Discovery and Development by Bringing AI-Enabled Analytics to FoundationInsights®
October 31, 2025
·
3 min read
Alzheimer’s disease
J&J’s Anti-Tau Bet Falls Flat in Mid-Stage Alzheimer’s Trial
Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau antibody failed to slow clinical decline in patients with early Alzheimer’s disease.
November 24, 2025
·
1 min read
·
Heather McKenzie
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
·
11 min read
Press Releases
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
November 28, 2025
·
12 min read
1 of 65,814
Next
